Biogen Company Profile (NASDAQ:BIIB)

About Biogen (NASDAQ:BIIB)

Biogen logoBiogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:BIIB
  • CUSIP: 09062X10
  • Web: www.biogen.com
Capitalization:
  • Market Cap: $71.48 billion
  • Outstanding Shares: 211,431,000
Average Prices:
  • 50 Day Moving Avg: $324.65
  • 200 Day Moving Avg: $285.82
  • 52 Week Range: $244.28 - $348.84
P/E:
  • Trailing P/E Ratio: 22.19
  • Foreward P/E Ratio: 14.50
  • P/E Growth: 2.39
Sales & Book Value:
  • Annual Revenue: $11.72 billion
  • Price / Sales: 6.10
  • Book Value: $54.79 per share
  • Price / Book: 6.17
Profitability:
  • EBITDA: $6.42 billion
  • Net Margins: 28.10%
  • Return on Equity: 37.42%
  • Return on Assets: 20.12%
Debt:
  • Debt-to-Equity Ratio: 0.51%
  • Current Ratio: 2.10%
  • Quick Ratio: 1.83%
Misc:
  • Average Volume: 1.28 million shs.
  • Beta: 0.77
  • Short Ratio: 2.28
 

Frequently Asked Questions for Biogen (NASDAQ:BIIB)

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) released its quarterly earnings results on Tuesday, July, 25th. The company reported $5.04 EPS for the quarter, beating the Zacks' consensus estimate of $4.36 by $0.68. The firm had revenue of $3.08 billion for the quarter, compared to analyst estimates of $2.81 billion. Biogen had a net margin of 28.10% and a return on equity of 37.42%. The company's revenue for the quarter was up 6.4% compared to the same quarter last year. During the same period in the previous year, the business earned $5.21 earnings per share. View Biogen's Earnings History.

When will Biogen make its next earnings announcement?

Biogen is scheduled to release their next quarterly earnings announcement on Tuesday, October, 24th 2017. View Earnings Estimates for Biogen.

What guidance has Biogen issued on next quarter's earnings?

Biogen updated its FY17 earnings guidance on Tuesday, July, 25th. The company provided earnings per share (EPS) guidance of $20.80-21.40 for the period, compared to the Thomson Reuters consensus estimate of $20.37. The company issued revenue guidance of $11.5-11.8 billion, compared to the consensus revenue estimate of $11.40 billion.

Where is Biogen's stock going? Where will Biogen's stock price be in 2017?

25 analysts have issued twelve-month target prices for Biogen's shares. Their forecasts range from $271.00 to $442.00. On average, they anticipate Biogen's stock price to reach $342.83 in the next year. View Analyst Ratings for Biogen.

What are analysts saying about Biogen stock?

Here are some recent quotes from research analysts about Biogen stock:

  • 1. Stifel Nicolaus analysts commented, "gigantic" aducanumab phase 3 trial, which started in 2015 and was 50 percent enrolled in the second quarter of 2017, Shrader commented in his upgrade note. This should be seen as a "no news is good news" scenario as the Data and Safety Monitoring Board has likely seen a lot of data and hasn't reported anything negative.Second, Biogen's partner Eisai is set to report an interim outlook at its plaque-busting mAb that targets the form of Ab plaque thought to lead to neuronal destruction, the analyst continued. The only possible negative outcome would be strong plaque removal with no hints of cognitive benefit and any other result could either be very good or OK.Third, Biogen's often ignored stroke programs address a very large market. Of particular note, the company's Tysabri stoke program uncovered the "same cognitive and energy benefits in stroke patients that are routinely reported in MS patients" and turning this effect into a clinical endpoint that would be acceptable for the U.S. Food and Drug Administration is the likely next step.Finally, Ocrelizumab as part of the company's base business is "meh not mud," the analyst added. The therapy remains a drug with "remarkable anti inflammatory properties," but a commercial rollout will likely be "measured." (10/17/2017)
  • 2. Mizuho analysts commented, "We looked through early Spinraza data to draw as close to apples to apples comparison as possible. Here is a chart we found (from an old BIIB deck), which shows Spinraza increases SMN protein by ~2.7x." (10/2/2017)
  • 3. Cantor Fitzgerald analysts commented, "A German patient treated for three years with Tysabri and then with a single dose of Ocrevus developed PML." (5/25/2017)
  • 4. Cowen and Company analysts commented, "Biogen reported Q1 revenues of $2.81B (+3% Y/Y, vs. consensus of $2.74B) and non-." (4/25/2017)
  • 5. Instinet analysts commented, "We are initiating on BIIB with a Buy rating and $345 target price. We recommend owning BIIB shares over the next 12 months given limited 2017 downside to revenue forecasts and potential Spinraza launch upside. We estimate that a successful Spinraza launch will drive above-consensus revenues of $11.6bn in 2017 and $12.2bn in 2018, despite flat MS-franchise growth that may be impacted by emerging competition (Ocrevus). We anticipate this return to growth will drive modest revenue multiple expansion and strong GAAP EPS growth - to $19.41 in 2017 and $21.56 in 2018, yielding upside to our $345 target price." (3/1/2017)

Who are some of Biogen's key competitors?

Who are Biogen's key executives?

Biogen's management team includes the folowing people:

  • Stelios B. Papadopoulos Ph.D., Independent Chairman of the Board
  • Michel Vounatsos, Chief Executive Officer, Director
  • Gregory F. Covino, Interim Principal Financial Officer, Chief Accounting Officer, Vice President - Finance
  • Ginger Gregory Ph.D., Chief Human Resource Officer, Executive Vice President
  • Kenneth A. Di Pietro, Executive Vice President - Human Resources
  • Susan H. Alexander Esq., Executive Vice President, Chief Legal Officer and Corporate Secretary
  • Michael D. Ehlers M.D., Ph.D., Executive Vice President, Head - Research and Development
  • Adriana Karaboutis, Executive Vice President - Technology , Business Solutions and Corporate Affairs
  • Jean-Paul Kress M.D., Executive Vice President, President - International and Head of Global Therapeutic Operations
  • Paul McKenzie Ph.D., Executive Vice President - Pharmaceutical Operations & Technology

Who owns Biogen stock?

Biogen's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include APG Asset Management N.V. (0.22%), Assenagon Asset Management S.A. (0.19%), Rockefeller Financial Services Inc. (0.12%), Fisher Asset Management LLC (0.05%), State Treasurer State of Michigan (0.03%) and Oakbrook Investments LLC (0.03%). Company insiders that own Biogen stock include Adam Koppel, Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.

Who sold Biogen stock? Who is selling Biogen stock?

Biogen's stock was sold by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan, Bridges Investment Counsel Inc., Rockefeller Financial Services Inc., Fisher Asset Management LLC, Verde Servicos Internacionais S.A., Bridges Investment Management Inc. and Mutual of America Capital Management LLC. Company insiders that have sold Biogen stock in the last year include Alfred Sandrock, Brian S Posner, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Insider Buying and Selling for Biogen.

Who bought Biogen stock? Who is buying Biogen stock?

Biogen's stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Oakbrook Investments LLC, APG Asset Management N.V., Barometer Capital Management Inc., Shell Asset Management Co., Meeder Asset Management Inc., Eqis Capital Management Inc. and Montrusco Bolton Investments Inc.. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

How do I buy Biogen stock?

Shares of Biogen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Biogen's stock price today?

One share of Biogen stock can currently be purchased for approximately $338.10.


MarketBeat Community Rating for Biogen (NASDAQ BIIB)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  1,148 (Vote Outperform)
Underperform Votes:  688 (Vote Underperform)
Total Votes:  1,836
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Biogen (NASDAQ:BIIB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 9 Hold Ratings, 15 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 2.68)
Consensus Price Target: $342.83 (1.40% upside)
Consensus Price Target History for Biogen (NASDAQ:BIIB)
Price Target History for Biogen (NASDAQ:BIIB)
Analysts' Ratings History for Biogen (NASDAQ:BIIB)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/18/2017Bank of America CorporationBoost Price TargetBuy$358.00 -> $365.00N/AView Rating Details
10/17/2017Morgan StanleyReiterated RatingBuyN/AView Rating Details
10/17/2017MizuhoUpgradeNeutral -> Buy$319.00 -> $400.00N/AView Rating Details
10/17/2017Stifel NicolausUpgradeHold -> Buy$300.00 -> $415.00N/AView Rating Details
10/5/2017Royal Bank Of CanadaReiterated RatingHold$315.00N/AView Rating Details
9/21/2017Raymond James Financial, Inc.DowngradeStrong-Buy -> Market Perform$244.28 -> $319.00LowView Rating Details
9/20/2017SunTrust Banks, Inc.Initiated CoverageBuy -> Buy$360.00LowView Rating Details
9/13/2017BMO Capital MarketsBoost Price TargetMarket Perform$328.00 -> $377.00LowView Rating Details
8/25/2017Robert W. BairdReiterated RatingHold$290.00LowView Rating Details
8/16/2017Goldman Sachs Group, Inc. (The)UpgradeBuy -> Conviction-Buy$338.00LowView Rating Details
7/27/2017Cowen and CompanyReiterated RatingBuyMediumView Rating Details
7/26/2017Deutsche Bank AGReiterated RatingBuy$315.00 -> $319.00LowView Rating Details
7/26/2017Leerink SwannReiterated RatingMarket Perform$304.00 -> $338.00HighView Rating Details
7/14/2017Credit Suisse GroupSet Price TargetHold$300.00LowView Rating Details
7/11/2017Jefferies Group LLCReiterated RatingHold -> Hold$310.00LowView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
5/25/2017Sanford C. BernsteinReiterated RatingOutperformLowView Rating Details
5/25/2017Cantor FitzgeraldReiterated RatingHold$277.00LowView Rating Details
5/15/2017Piper Jaffray CompaniesSet Price TargetBuy$332.00 -> $442.00LowView Rating Details
4/23/2017Barclays PLCReiterated RatingOverweight$380.00 -> $360.00MediumView Rating Details
4/4/2017Citigroup Inc.Boost Price TargetBuy$305.00 -> $315.00LowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$223.03 -> $345.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageNeutralN/AView Rating Details
1/30/2017HC WainwrightReiterated RatingBuy$360.00N/AView Rating Details
1/18/2017J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
8/2/2016Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
6/8/2016Wells Fargo & CompanyReiterated RatingBuyN/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageOverweight$344.00N/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Biogen (NASDAQ:BIIB)
Earnings by Quarter for Biogen (NASDAQ:BIIB)
Earnings History by Quarter for Biogen (NASDAQ BIIB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/24/2017$5.61N/AView Earnings Details
7/25/2017Q2 2017$4.36$5.04$2.81 billion$3.08 billionViewN/AView Earnings Details
4/25/2017Q1 2017$4.97$5.20$2.73 billion$2.81 billionViewN/AView Earnings Details
1/26/2017Q416$4.96$5.04$2.94 billion$2.87 billionViewN/AView Earnings Details
10/26/2016Q316$4.97$5.19$2.91 billion$2.96 billionViewListenView Earnings Details
7/21/2016Q216$4.69$5.21$2.79 billion$2.89 billionViewListenView Earnings Details
4/21/2016Q116$4.47$4.79$2.75 billion$2.73 billionViewListenView Earnings Details
1/27/2016Q415$4.08$4.50$2.70 billion$2.84 billionViewListenView Earnings Details
10/21/2015Q315$3.80$4.48$2.65 billion$2.39 billionViewListenView Earnings Details
7/24/2015Q215$4.10$4.22$2.71 billion$2.59 billionViewListenView Earnings Details
4/24/2015Q115$3.91$3.82$2.66 billion$2.56 billionViewListenView Earnings Details
1/29/2015Q414$3.74$4.09$2.64 billion$2.60 billionViewListenView Earnings Details
10/22/2014Q3$3.22$3.80$2.48 billion$2.50 billionViewListenView Earnings Details
7/23/2014Q214$2.80$3.49$2.14 billion$2.42 billionViewListenView Earnings Details
4/23/2014Q114$2.56$2.47$2.00 billion$2.10 billionViewListenView Earnings Details
1/29/2014Q413$2.27$2.34$1.93 billion$2.00 billionViewListenView Earnings Details
10/28/2013Q313$2.10$2.35$1.78 billion$1.83 billionViewListenView Earnings Details
7/25/2013Q2 2013$1.93$2.30$1.62 billion$1.70 billionViewListenView Earnings Details
4/25/2013Q1 2013$1.63$1.97$1.41 billion$1.40 billionViewListenView Earnings Details
1/28/2013Q4 2012$1.46$1.40$1.38 billion$1.40 billionViewListenView Earnings Details
10/25/2012$1.60$1.91ViewN/AView Earnings Details
7/24/2012$1.56$1.82ViewN/AView Earnings Details
5/1/2012$1.49$1.40ViewN/AView Earnings Details
1/31/2012$1.49$1.51ViewN/AView Earnings Details
10/28/2011$1.52$1.61ViewN/AView Earnings Details
7/26/2011$1.36$1.36ViewN/AView Earnings Details
4/21/2011$1.41$1.43ViewN/AView Earnings Details
2/1/2011$1.23$1.42ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Biogen (NASDAQ:BIIB)
2017 EPS Consensus Estimate: $20.39
2018 EPS Consensus Estimate: $24.24
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$4.47$5.03$4.75
Q2 20173$3.92$4.11$4.04
Q3 20174$5.69$6.16$5.92
Q4 20175$4.94$6.07$5.68
Q1 20182$5.70$5.88$5.79
Q2 20182$5.95$6.22$6.09
Q3 20182$6.11$6.17$6.14
Q4 20182$6.20$6.24$6.22
Q1 20191$6.30$6.30$6.30
Q2 20191$6.53$6.53$6.53
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Biogen (NASDAQ:BIIB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Biogen (NASDAQ:BIIB)
Insider Ownership Percentage: 0.25%
Institutional Ownership Percentage: 87.62%
Insider Trades by Quarter for Biogen (NASDAQ:BIIB)
Institutional Ownership by Quarter for Biogen (NASDAQ:BIIB)
Insider Trades by Quarter for Biogen (NASDAQ:BIIB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/25/2017Susan H AlexanderEVPSell4,974$290.01$1,442,509.74View SEC Filing  
7/19/2017Susan H AlexanderEVPSell7,758$285.00$2,211,030.00View SEC Filing  
6/9/2017Brian S PosnerDirectorSell1,084$256.31$277,840.04View SEC Filing  
5/1/2017Michel VounatsosCEOBuy1,402$271.35$380,432.70View SEC Filing  
4/27/2017Alexander J. DennerDirectorBuy73,858$278.50$20,569,453.00View SEC Filing  
4/25/2017Paul J ClancyVPSell9,892$290.00$2,868,680.00View SEC Filing  
4/3/2017Alfred SandrockCMOSell1,981$274.08$542,952.48View SEC Filing  
3/13/2017Paul J ClancyVPSell9,891$291.55$2,883,721.05View SEC Filing  
2/27/2017Michel VounatsosCEOBuy1,333$285.39$380,424.87View SEC Filing  
1/9/2017Robert W PangiaDirectorSell5,450$295.39$1,609,875.50View SEC Filing  
10/4/2016Adriana KaraboutisEVPSell262$311.94$81,728.28View SEC Filing  
10/3/2016Adriana KaraboutisEVPSell380$313.00$118,940.00View SEC Filing  
9/22/2016Caroline DorsaDirectorSell27,570$314.00$8,656,980.00View SEC Filing  
7/21/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
6/6/2016Adam KoppelEVPSell555$290.00$160,950.00View SEC Filing  
6/3/2016George A ScangosCEOSell842$290.00$244,180.00View SEC Filing  
6/1/2016George A ScangosCEOSell3,855$289.74$1,116,947.70View SEC Filing  
5/25/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
5/2/2016George A ScangosCEOSell487$274.74$133,798.38View SEC Filing  
4/6/2016Adam KoppelEVPSell102$275.00$28,050.00View SEC Filing  
4/6/2016George A ScangosCEOSell157$280.00$43,960.00View SEC Filing  
4/1/2016George A ScangosCEOSell487$258.83$126,050.21View SEC Filing  
3/1/2016George A ScangosCEOSell487$261.37$127,287.19View SEC Filing  
2/25/2016Adriana KaraboutisEVPSell84$261.90$21,999.60View SEC Filing  
2/25/2016Alfred SandrockCMOSell183$261.90$47,927.70View SEC Filing  
2/17/2016Alfred SandrockChief Medical OfficerSell722$256.16$184,947.52View SEC Filing  
2/17/2016George A ScangosCEOSell487$256.16$124,749.92View SEC Filing  
2/9/2016Alfred SandrockChief Medical OfficerSell852$246.54$210,052.08View SEC Filing  
12/4/2015Alfred SandrockCMOSell441$277.00$122,157.00View SEC Filing  
10/23/2015Alexander J DennerDirectorBuy310,000$277.47$86,015,700.00View SEC Filing  
7/27/2015Stelios PapadopoulosDirectorBuy10,000$304.88$3,048,800.00View SEC Filing  
6/19/2015Douglas E WilliamsEVPSell3,841$410.00$1,574,810.00View SEC Filing  
6/1/2015George A ScangosCEOSell1,362$398.87$543,260.94View SEC Filing  
4/1/2015George A ScangosCEOSell1,362$423.20$576,398.40View SEC Filing  
3/25/2015John CoxEVPSell12,010$449.06$5,393,210.60View SEC Filing  
3/20/2015Eric K RowinskyDirectorSell11,667$475.00$5,541,825.00View SEC Filing  
3/19/2015Eric K RowinskyDirectorSell2,333$436.14$1,017,514.62View SEC Filing  
3/17/2015Eric K RowinskyDirectorSell4,667$425.45$1,985,575.15View SEC Filing  
3/10/2015Robert W PangiaDirectorSell3,625$413.40$1,498,575.00View SEC Filing  
3/2/2015Alfred SandrockSVPSell3,174$409.49$1,299,721.26View SEC Filing  
2/17/2015Steven H HoltzmanEVPSell2,128$389.11$828,026.08View SEC Filing  
2/10/2015Alfred SandrockSVPSell1,143$398.11$455,039.73View SEC Filing  
2/2/2015Kenneth DipietroEVPSell1,656$389.03$644,233.68View SEC Filing  
12/15/2014Spyridon Artavanis-TsakonasSVPSell1,981$346.50$686,416.50View SEC Filing  
12/2/2014Steven H HoltzmanEVPSell1,749$335.65$587,051.85View SEC Filing  
11/11/2014Steven H HoltzmanEVPSell1,750$330.00$577,500.00View SEC Filing  
11/3/2014George A ScangosCEOSell1,128$320.78$361,839.84View SEC Filing  
10/1/2014George A ScangosCEOSell1,127$330.97$373,003.19View SEC Filing  
10/1/2014Steven H HoltzmanEVPSell1,750$330.97$579,197.50View SEC Filing  
8/1/2014George A ScangosCEOSell1,128$332.93$375,545.04View SEC Filing  
7/16/2014George A ScangosCEOSell12,316$312.37$3,847,148.92View SEC Filing  
5/19/2014Steven HoltzmanEVPSell1,221$289.15$353,052.15View SEC Filing  
5/1/2014George ScangosCEOSell2,123$285.56$606,243.88View SEC Filing  
4/17/2014Steven HoltzmanEVPSell1,221$291.00$355,311.00View SEC Filing  
4/1/2014George ScangosCEOSell2,123$308.42$654,775.66View SEC Filing  
4/1/2014Robert PangiaDirectorSell6,250$308.42$1,927,625.00View SEC Filing  
3/31/2014Brian PosnerDirectorSell3,000$296.76$890,280.00View SEC Filing  
3/20/2014Caroline DorsaDirectorSell10,000$348.88$3,488,800.00View SEC Filing  
3/19/2014Douglas WilliamsEVPSell3,505$352.29$1,234,776.45View SEC Filing  
3/17/2014Steven HoltzmanEVPSell1,221$334.83$408,827.43View SEC Filing  
3/11/2014Stuart KingsleyEVPSell8,428$336.83$2,838,803.24View SEC Filing  
3/3/2014George ScangosCEOSell2,942$335.79$987,894.18View SEC Filing  
2/26/2014Alfred SandrockSVPSell1,048$342.17$358,594.16View SEC Filing  
2/18/2014Steven HoltzmanEVPSell1,222$327.90$400,693.80View SEC Filing  
2/13/2014Kenneth DipietroEVPSell1,290$316.81$408,684.90View SEC Filing  
2/11/2014Alfred SandrockSVPSell2,085$314.31$655,336.35View SEC Filing  
2/11/2014George ScangosCEOSell2,456$314.31$771,945.36View SEC Filing  
2/4/2014Kenneth DipietroEVPSell1,655$299.01$494,861.55View SEC Filing  
1/21/2014Eric RowinskyDirectorSell2,020$310.09$626,381.80View SEC Filing  
1/15/2014Lynn SchenkDirectorSell1,000$297.48$297,480.00View SEC Filing  
1/8/2014William YoungDirectorSell15,000$285.11$4,276,650.00View SEC Filing  
1/6/2014Robert PangiaDirectorSell6,250$278.03$1,737,687.50View SEC Filing  
12/2/2013Lynn SchenkDirectorSell1,000$291.71$291,710.00View SEC Filing  
11/22/2013Raymond PawlickiSVPSell4,000$288.00$1,152,000.00View SEC Filing  
11/1/2013George A ScangosCEOSell2,239$245.57$549,831.23View SEC Filing  
11/1/2013Lynn SchenkDirectorSell1,000$245.00$245,000.00View SEC Filing  
10/22/2013Alfred SandrockSVPSell15,030$250.11$3,759,153.30View SEC Filing  
9/18/2013Paul ClancyCFOSell26,785$245.00$6,562,325.00View SEC Filing  
9/17/2013Steven HoltzmanEVPSell3,501$238.98$836,668.98View SEC Filing  
9/16/2013Paul ClancyCFOSell99,030$238.27$23,595,878.10View SEC Filing  
9/16/2013Raymond PawlickiSVPSell4,000$238.03$952,120.00View SEC Filing  
9/3/2013George ScangosCEOSell2,239$214.40$480,041.60View SEC Filing  
8/26/2013Douglas WilliamsEVPSell4,368$211.35$923,176.80View SEC Filing  
8/1/2013George A ScangosCEOSell2,239$218.82$489,937.98View SEC Filing  
7/16/2013George A ScangosCEOSell2,239$223.94$501,401.66View SEC Filing  
6/14/2013Alexander J DennerDirectorSell2,900$212.00$614,800.00View SEC Filing  
6/11/2013Brian S PosnerDirectorSell2,020$219.62$443,632.40View SEC Filing  
6/10/2013Lynn SchenkDirectorSell2,000$225.82$451,640.00View SEC Filing  
6/3/2013George A ScangosCEOSell1,598$234.16$374,187.68View SEC Filing  
6/3/2013Stephen A SherwinDirectorSell12,825$233.26$2,991,559.50View SEC Filing  
5/28/2013Robert W PangiaDirectorSell5,900$237.23$1,399,657.00View SEC Filing  
12/27/2012Alexander J DennerDirectorSell7,980$148.62$1,185,987.60View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Biogen (NASDAQ:BIIB)
Latest Headlines for Biogen (NASDAQ:BIIB)
Source:
Loading headlines, please wait.

Social

Chart

Biogen (BIIB) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.